Imipenem/Cilastatin
(Primaxin) |
Category:
Description:
Indications:
-
Lower respiratory tract infections (S.
aureus, E. coli, H. influenzae, H.
parainfluenzae, Klebsiella species, Enterobacter species, Acetinobacter species, Serratia species)
-
Urinary tract infections (Enterococcus faecalis, S. aureus, E. coli, Klebsiella species, Proteus
vulgaris, Enterobacter species, Providencia
rettgeri, Morganella morganii, Pseudomonas aeruginosa)
-
Intra-abdominal infections (E. faecalis, S. aureus, E. coli, S. epidermidis, Streptococcus species, Enterobacter species,
Klebsiella species, Bacteroides species, Proteus species, M. mogranii, P. aeruginosa, Citrobacter species, Peptococcus species, Peptostreptococcus species, Bacteroides species, Fusobacterium species, Eubacterium species, Propionibacterium species, Bifidobacterium species)
-
Gynecological infections (E. faecalis, S. aureus, S. epidermidis, Streptococcus agalactiae, E.
coli, Klebsiella species, Proteus species, Enterobacter species, Bifidobacterium species, Bacteroides species, Gardnerella
vaginalis, , Peptococcus species, Peptostreptococcus species, Propionibacterium species)
-
Bacterial septicemia (E. faecalis, S. aureus, E. coli, Klebsiella species, P.
aeruginosa, Serratia species, Enterobacter species, Bacteroides species)
-
Bone and joint infections (E. faecalis, S. aureus, S. epidermidis, Enterobacter species, P.
aeruginosa)
-
Skin infections (E.
faecalis, S. aureus, S. epidermidis, E. coli, Klebsiella species, Enterobacter species, P. vulgaris, P.
rettgeri, M. morganii, P. aeruginosa, Serratia species, Citrobacter species, Peptococcus species, Peptostreptococcus species, Acinetobacter species, Fusobacterium species, Bacteroides species)
-
Endocarditis (S.
aureus)
-
Polymicrobic infections (S. pneumoniae, S. pyogenes, S. aureus, P. aeruginosa)
Contraindications:
Precautions:
-
Pregnancy
category C
-
Use
with caution in patients with PCN or cephalosporin allergy (5-10%
chance of cross-reactivity)
-
Use
in caution with patients having CNS disorders (brain lesions, seizure
history) due to increased risk of CNS side effects (see below).
-
Use
alternate form of birth control (disrupts absorption of oral
contraceptives and renders them inactive)
-
Dosage
modifications are generally only required in patients with severe
renal impairment
-
IM
injection dosages over 1500mg per day are not recommended
Adverse
Reactions (Side Effects):
-
CNS:
fever (0.5%), seizures (0.4%), dizziness, somnolence, tremor,
confusion, headache, hallucinations
-
Dermatological:
rash, pruritis, urticaria
-
Gastrointestinal:
nausea (2%), diarrhea, vomiting
-
Local
pain at injection site
-
Hearing
loss, tinnitis, taste changes
-
Pediatric
patients: diarrhea (4%), phlebitis (2.2%)
-
Newborns
to 3 months: convulsions (6%), diarrhea (3%)
|
Dosage:
Administered
by IM or IV injection over 40-60 minutes for >500mg/dose, over 15-30
minutes for <500mg/dose
-
Adult
(> 60kg):
-
mild
infection: 250-500mg q6h (totally daily dose 2 grams)
-
moderate
infections: 500mg q6-8h (total daily dose 2-3 grams)
-
severe
infections: 500mg q6h (total daily dose 3-4 grams)
-
uncomplicated
UTI: 250mg q6h (totally daily dose 1 gram)
-
complicated
UTI: 500mg q6h (total daily dose 2 grams)
-
Pediatric
(>3 months):
-
Pediatric
(<3 months):
-
<1
week: 25mg/kg q12h
-
1-4
weeks: 25mg/kg q8h
-
1-3
months: 25mg q6h
-
Child
(< 60kg):
|
|
|
|
The information contained here is an
abbreviated summary. For more detailed and complete information, consult the
manufacturer's product information sheets or standard textbooks
Source: Operational Medicine 2001, Health
Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau
of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington,
D.C., 20372-5300
This information is provided by The Brookside Associates. The Brookside
Associates, LLC. is a private organization, not affiliated with any governmental
agency. The opinions presented here are those of the author and do not
necessarily represent the opinions of the Brookside Associates or the Department
of Defense. The presence of any advertising on these pages does not constitute
an endorsement of that product or service by either the US Department of Defense
or the Brookside Associates. All material presented here is unclassified.
C. 2009, 2014, All Rights Reserved
|
|